Incorporation of doxorubicin and CoFe2O4 nanoparticles into the cellulose acetate phthalate / polyvinyl alcohol (core)/ polyurethane (shell) nanofibers against A549 human lung cancer during chemotherapy/hyperthermia combined method.

Cellulose acetate phthalate (CAP)/polyvinyl alcohol (PVA)/polyurethane (PU) nanofibers were synthesized by simple and coaxial electrospinning (ES) processes. Doxorubicin (DOX) and the CoFe2O4 nanoparticles were loaded into the nanofibers. The performance of the prepared nanofibers was investigated for the sustained release of DOX against A541 lung cancer cells under chemotherapy/external magnetic field (EMF) and alternating magnetic field (AMF, hyperthermia treatment) combined methods in both the in vitro and in vivo conditions. The sustained release of DOX from core-shell nanofibers containing 5 wt% cobalt ferrite was obtained within 300, 600 h, at pH of 5.5 and 7.4 without AMF and 168, 360 h, under an alternating magnetic field (AMF). More than 98.3 ± 0.2 % of A549 cancer cells were killed in the presence of core-shell nanofibers containing 100 µg DOX and 5 % cobalt ferrite nanoparticles in the presence of AMF. The flowcytometric results indicated that only 19.1 and 8.85 % cancer cells remained alive under EMF and AMF, respectively. The in vivo results revealed in stopping the growth of tumor volume and decrease in the relative tumor volume up to 0.5 were obtained using magnetic core-shell nanofibers containing 100 µg DOX and 5 % cobalt ferrite nanoparticles in the presence of EMF and AMF, respectively.

Paclitaxel-loaded liposome-incorporated chitosan (core)/poly(ε-caprolactone)/chitosan (shell) nanofibers for the treatment of breast cancer.

Liposomes and nanofibers have been introduced as effective drug delivery systems of anticancer drugs. The performance of chitosan (core)/poly(ε-caprolactone) (PCL)/paclitaxel simple nanofibers, chitosan/paclitaxel (core)/PCL/chitosan (shell) nanofibers and paclitaxel-loaded liposome-incorporated chitosan (core)/PCL-chitosan (shell) nanofibers was investigated for the controlled release of paclitaxel and the treatment of breast cancer. The synthesized formulations were characterized using polydispersity index, dynamic light scattering, zeta potential, scanning electron microscopy, transmission electron microscopy, and Fourier transform infrared analysis. The sustained release of paclitaxel from liposome-loaded nanofibers was achieved within 30 days. The release data was best described using Korsmeyer-Peppas pharmacokinetic model. The cell viabilities of synthesized nanofibrous samples were higher than 98 % ± 1 % toward L929 normal cells after 168 h. The maximum cytotoxicity against MCF-7 breast cancer cells was 85 % ± 2.5 % using liposome-loaded core-shell nanofibers. The in vivo results indicated the reduction of tumor weight from 1.35 ± 0.15 g to 0.65 ± 0.05 g using liposome-loaded core-shell nanofibers and its increasing from 1.35 ± 0.15 g to 3.2 ± 0.2 g using pure core-shell nanofibers. The three-stage drug release behavior of paclitaxel-loaded liposome-incorporated core-shell nanofibers and the high in vivo tumor efficiency suggested the development of these formulations for cancer treatment in the future.

UiO-66 metal organic framework nanoparticles loaded carboxymethyl chitosan/poly ethylene oxide/polyurethane core-shell nanofibers for controlled release of doxorubicin and folic acid.

Doxorubicin (DOX) and folic acid (FA) were incorporated into the UiO-66 metal organic framework (MOF) and following were loaded into the carboxymethyl chitosan/poly ethylene oxide (PEO)/polyurethane core-shell nanofibers for controlled release of DOX and FA toward MCF-7 cells death. The synthesized nanocarriers were characterized using TEM, XRD, and SEM analysis. The drug loading efficiency and release profiles of DOX/MOF and FA/MOF from synthesized nanofibers have been investigated. The fitting of kinetic data by the pharmacokinetic models demonstrated the non-Fickian diffusion from nanofibers and Fickian diffusion from core-shell fibers. The cytotoxicity of synthesized nanofibers toward MCF-7 cancer cells was evaluated using DAPI staining, MTT assay and flow cytometry tests to investigate the simultaneous use of DOX and FA in the nanofibrous matrix for MCF-7 cells death in vitro. The maximum cell death using DOX-FA loaded-core-shell fibers produced by coaxial electrospinning method under 0.3, 0.5 and 0.8 mLh-1 shell flow rates were found to be 82 ± 0.7, 83 ± 0.5 and 87 ± 0.5% after 168, 240 and 240 h, respectively. The cytotoxicity results indicated that the co-delivery of DOX and FA into the core-shell fibers could be widely used for various cancers treatment.

Synthesis of chitosan-grafted-poly(N-vinylcaprolactam) coated on the thiolated gold nanoparticles surface for controlled release of cisplatin.

The gold nanoparticles surface was modified by thioglycolic acid ligand and their surface was coated by the chitosan-grafted-poly(N-vinylcaprolactam) (chitosan-g-PNVCL) copolymer. The cisplatin anticancer drug was loaded into the synthesized nanocarriers and its performance was investigated for the treatment of MCF-7 breast cancer cells in vitro. The synthesized nanoparticles were characterized using FTIR, DLS, TEM, SEM, EDX and TGA analysis. The lower critical solution temperature (LCST) of PNVCL/chitosan and PNVCL/chitosan coated gold nanoparticles were found to be 38 and 39 °C, respectively. The cisplatin loading efficiency, cisplatin release from nanoparticles at different temperatures and pH values as well as the pharmacokinetic studies were examined. The maximum cisplatin release from nanoparticles was achieved at T > LCST (42 °C) and pH of 5. The Korsemeyer-Peppas model was best described the cisplatin release from nanoparticles. The maximum MCF cell death was found to be 92% using cisplatin loaded-gold/TGA/chitosan-g-PNVCL nanoparticles under an induction heating system.